`
`__________
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`__________
`
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owner
`
`__________
`
`
`Case IPR2021-00816
`Patent 9,220,631
`
`__________
`
`
`DECLARATION OF JUERGEN SIGG, PH.D., IN SUPPORT OF
`NOVARTIS’S
`PATENT OWNER RESPONSE
`
`
`
`
`
`
`Novartis Exhibit 2206.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`TABLE OF CONTENTS
`
`INTRODUCTION .......................................................................................... 2
` I.
`II. GENENTECH TRIED TO DEVELOP A TERMINALLY
`STERILIZED PFS FOR INTRAVITREAL INJECTION OF A VEGF
`ANTAGONIST BUT FAILED ...................................................................... 2
`III. SILICONE OIL LEVELS IN COMMERCIALLY AVAILABLE
`SYRINGES ..................................................................................................... 7
`IV. VETTER’S SKEPTICISM THAT A PFS COULD FUNCTION
`PROPERLY WITH LESS THAN 100 µG OF SILICONE OIL ................... 9
`V. NOVARTIS WAS NOT ABLE TO TERMINALLY STERILIZE
`THE LUCENTIS PFS WITH THE PROCESS DESCRIBED IN WO
`’877 ............................................................................................................... 11
`VI. NOVARTIS REDESIGNED IMPORTANT ASPECTS OF THE
`SYRINGE AFTER FILING WO ’877 BUT BEFORE
`COMPLETING DEVELOPMENT OF THE LUCENTIS PFS ................... 14
`VII. TESTING OF LUCENTIS PFS ................................................................... 16
`VIII. GENENTECH LICENSE ............................................................................. 18
`IX. DECLARATION .......................................................................................... 20
`
`
`
`
`
`
`
`
`
`
`1
`
`
`
`Novartis Exhibit 2206.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`I, Juergen Sigg, declare and state as follows:
`I.
`INTRODUCTION
`1.
`I am an Executive Director of Science and Technology in Biologics
`
`Drug Product Development at Novartis Pharma AG (“Novartis”). As part of my
`
`duties at Novartis, I serve as the lead scientist for formulation and process
`
`development of assigned biologic drug products.
`
`2.
`
`I have a degree in pharmaceutical science and a Ph.D. in
`
`pharmaceutical technology. Over the course of my career at Novartis, I have been
`
`the lead formulation and process development scientist on several prefilled syringe
`
`(“PFS”) products. My work in this area began in 1995, and continues to this day.
`
`Several of the PFS products I worked on, including Xolair® and Extavia®, made it
`
`to the market. Relevant here, I served as the technical lead in the development of
`
`the Lucentis® PFS.
`
`3.
`
`I am a named inventor on several patents and patent applications,
`
`including U.S. Patent No. 9,220,631 (“’631 patent”) and the abandoned patent
`
`application WO 2011/006877 (“WO ’877”).
`
`4.
`
`I have personal knowledge of the facts set forth below.
`
`II. GENENTECH TRIED TO DEVELOP A TERMINALLY
`STERILIZED PFS FOR INTRAVITREAL INJECTION OF A VEGF
`ANTAGONIST BUT FAILED
`5.
`Lucentis is the brand name for a compound discovered by Genentech
`
`called ranibizumab. Ranibizumab functions as a VEGF antagonist and is used to
`2
`
`
`
`Novartis Exhibit 2206.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`treat degenerative eye diseases. Lucentis is administered through intravitreal
`
`injection into the eye.
`
`6.
`
`.
`
`7.
`
`
`
`.
`
`8.
`
`
`
`
`
`9.
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` .
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`
`.
`
`4
`}
`
`Novartis Exhibit 2206.005
`Regeneron v. Novartis, IPR202 1-008 16
`
`
`
`
`
`10.
`
`———oS
`
`11.
`
`12.
`— S
`
`Novartis Exhibit 2206.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`13.
`
`——>we
`
`14.
`
`
`
`15.
`— dl
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.006
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`16.
`
`I have reviewed WO 2008/077155 (“Lam”), Ex. 1029. Xanthe Lam,
`
`the first named inventor on the patent application,
`
`
`
`17.
`
`
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.007
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`.
`
`18.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`III. SILICONE OIL LEVELS IN COMMERCIALLY AVAILABLE
`SYRINGES
`19.
`
` Novartis embarked on a
`
`project to design its own novel PFS. I was appointed pharmaceutical development
`
`lead of this project in late 2008. One of the design elements I focused on was the
`
`amount of silicone oil in the syringe. A PFS requires lubrication, usually
`
`pharmaceutical grade silicone oil, in order to function properly because of the
`
`friction between the syringe’s glass barrel and its plunger. If there is too little
`
`silicone oil, and therefore too much friction, it will take excessive force to move
`
`
`
`7
`
`Novartis Exhibit 2206.008
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`the plunger, resulting in difficulty to the physician in administering the injection
`
`and possible damage to the patient’s eye during injection.
`
`20.
`
`
`
`
`
`
`
`
`
`-
`
`
`
`21.
`
`.
`
`-
`
`
`
`8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.009
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`22.
`
`IV. VETTER’S SKEPTICISM THAT A PFS COULD FUNCTION
`PROPERLY WITH LESS THAN 100 µg OF SILICONE OIL
`23.
`
`24.
`
`25.
`
`
`
`.
`
`.
`
`
`
`9
`
`
`
`
`
`.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.0010
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`26.
`
`NNNoo_D
`
`27.
`
`28.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10
`
`Novartis Exhibit 2206.0011
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.0011
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`■
`
`.
`
`
`
`-
`
`V. NOVARTIS WAS NOT ABLE TO TERMINALLY STERILIZE THE
`LUCENTIS PFS WITH THE PROCESS DESCRIBED IN WO ’877
`30.
`In addition to having low silicone oil levels, we also intended the
`
`Lucentis PFS to be terminally sterilized, which, in the case of a syringe like the
`
`Lucentis PFS, refers to sterilizing the outer surface of the PFS in its final protective
`
`packaging.
`
`31.
`
`
`
`
`
`11
`
`
`
`
`
`Novartis Exhibit 2206.0012
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`32.
`
`33.
`
`-1o*)OoGoGoGo
`
`34.
`
`
`
`35.
`
`36.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`12
`
`Novartis Exhibit 2206.0013
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.0013
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`.
`
`
`
`37.
`
`
`
`38.
`
`39.
`
`
`
`
`
`40. Ex. 1007 is a copy of patent application WO ’877.
`
`
`
`13
`
`Novartis Exhibit 2206.0014
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`.
`
`
`
`VI. NOVARTIS REDESIGNED IMPORTANT ASPECTS OF THE
`SYRINGE AFTER FILING WO ’877 BUT BEFORE COMPLETING
`DEVELOPMENT OF THE LUCENTIS PFS
`41. During Novartis’s development of the Lucentis PFS, we determined
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`.
`
`
`
`14
`
`42.
`
`43.
`
`(
`
`
`
`Novartis Exhibit 2206.0015
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`44.
`
`EN£mn-
`
`45.
`
`
`
`46.
`BROn
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`15
`
`Novartis Exhibit 2206.0016
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.0016
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`47.
`
`48.
`
`
`
`
`
`
`
`VII. TESTING OF LUCENTIS PFS
`49.
`
`50.
`
`
`
`
`
`16
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.0017
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`51.
`—
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`17
`— ~
`
`Novartis Exhibit 2206.0018
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.0018
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`VIII. GENENTECH LICENSE
`52.
`
`53.
`
`
`
`18
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2206.0019
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`19
`19
`
`Novartis Exhibit 2206.0020
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2206.0020
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`IX. DECLARATION
`
`54.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by fine
`
`or imprisonment, or both, under Section 1001 of Title 18 of the United States
`
`Code.
`
`Dated: January 18, 2022
`
`Digitally signed by Sigg
`Juergen
`ON: dc=com, dc=novartls,
`ou"'"peoplo, ou~Go,
`serialNumber= 196126,
`
`S I• g g
`J uergen ~:~:;~~~~1.~;2,:0631
`By: /Juergen Sigg2 Ph.D./
`Juergen Sigg, Ph.D.
`
`+01'00'
`
`20
`
`Novartis Exhibit 2206.0021
`Regeneron v. Novartis, IPR2021-00816
`
`